Progressive Supranuclear Palsy (PSP) has been used to denote a unifying disorder
with progressive parkinsonism with early falls, vertical supranuclear gaze
palsy, pseudobulbar dysfunction and cognitive decline. Over the last decade,
heterogeneity of the disease into different clinical subtypes has been recognized
in clinicopathological studies. Although neuroimaging features and laboratory
findings may support the diagnosis, true biomarkers are still lacking in the clinical
setting. Neuronal and glial tau positive aggregates are predominantly found in basal
ganglia and brainstem, and the significant association of PSP with the common H1
tau haplotype likely points to a pathophysiological role of the tau protein in the
disease process. Future genetic studies of familial cases and an ongoing genomewide
association study of large series of pathological-proven cases may reveal
additional genetic factors in the near future.
http://repub.eur.nl/res/pub/30603/111202_Donker%20Kaat%2C%20Laura_bewerkt.pdf
http://repub.eur.nl/res/pub/30603/111202_Donker%20Kaat%2C%20Laura_bewerkt.pdf
No comments:
Post a Comment